The site where students compete, learn, and make money Wednesday, June 25, 2008
DJIA: 4.4 NASD: 32.98 10-YR: 0.01
 
 
 
 
     
 
     

Johnson & Johnson Pharmaceutical Review (NYSE: JNJ)

Submitted by lucas20 on Wed, 01/30/2008 - 22:42.

Dow component Johnson & Johnson Inc. (NYSE: JNJ) recently reported 4Q07 earnings of $0.88 and FY07 EPS of $4.15, a 10% increase from 2006 and $0.02 above analysts estimates. I will take this time to provide you with an overview of the company's pharmaceutical portfolio and its outlook for FY08.

In 2007, pharmaceutical sales increased 4% overall (6% ex-US).

EXISTING DRUGS
1) Topamax - Strong 07 performer, approval for epilepsy treatment in 07, boost from usage as migraine prevention, mostly US, generic competition in 09?

2) Levaquin - Strong 07 performer, growth in international sales buoyed 07 revenues, increased competition in US

3) Risperdal (Consta and Invega) - Strong 07 performer, but older version hurt by generic competition in international markets, patent being challenged by generics in US.

4) Remicade - Strong 07 performer, increased competition
from other biologics, strong international growth

5) Aciphex - Strong 07 performer, patent being challenged by generics

6) Concerta - Strong 07 performer, possible generic in the wings as JNJ asks FDA for clinical trials

7) Velcade - Strong 07 performer, pending EU approval for use on multiple myeloma

8) Eprex/Procrit - 12% decline in revenue, safety concerns, competition (Amgen/Aranesp), competition in Europe (Roche/Mircera), Medicare restrictions

9) Duragesic - generic competition started in 07

10) Ultracet - generic competition started in 07

11) Sporanox - generic competition started in 2007

12) Ortho Tri-Cyclen - huge competition for oral contraceptives, patent being challenged by generics

13) Razadyne - patent being challenged by generics

DRUG PIPELINE
1) Doribax - approved in Oct 07 for UTIs, pending for pneumonia, and on all accounts in EU

2) Intelence - HIV/AIDS drug approved this month

3) A schizophrenia drug coming online possible Fall 2008

4) Depoxetene in Europe for premature ejaculation, possible 08 market date

5) Cefpobritole for complicated skin infections and pneumonia, possible 08 market date

6) A drug for plaque psoriasis, possible 08 market date

7) Tapentadol filing for approval in 08

8) Rivaroxaban for knee and hip replacement patients filing in 08

9) A drug to treat RA , filing for approval in 08

10) Telaprevir for hep C, filing for approval in 2010

11) an oral factor Xa inhibitor strong Phase III results

Feel free to post updates or corrections.


»